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ABSTRACT This study aimed to describe real-life microbiological testing of adults hospitalised with
community-acquired pneumonia (CAP) and to assess concordance with the 2007 Infectious Diseases Society of
America (IDSA)/American Thoracic Society (ATS) and 2011 European Respiratory Society (ERS) CAP guidelines.
This was a cohort study based on the Global Initiative for Methicillin-resistant Staphylococcus aureus
Pneumonia (GLIMP) database, which contains point-prevalence data on adults hospitalised with CAP
across 54 countries during 2015.
In total, 3702 patients were included. Testing was performed in 3217 patients, and included blood
culture (71.1%), sputum culture (61.8%), Legionella urinary antigen test (30.1%), pneumococcal urinary
antigen test (30.0%), viral testing (14.9%), acute-phase serology (8.8%), bronchoalveolar lavage culture
(8.4%) and pleural fluid culture (3.2%). A pathogen was detected in 1173 (36.5%) patients. Testing
attitudes varied significantly according to geography and disease severity. Testing was concordant with
IDSA/ATS and ERS guidelines in 16.7% and 23.9% of patients, respectively. IDSA/ATS concordance was
higher in Europe than in North America (21.5% versus 9.8%; p<0.01), while ERS concordance was higher
in North America than in Europe (33.5% versus 19.5%; p<0.01).
Testing practices of adults hospitalised with CAP varied significantly by geography and disease severity. There
was a wide discordance between real-life testing practices and IDSA/ATS/ERS guideline recommendations.
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Introduction
Community-acquired pneumonia (CAP) is a leading cause of hospitalisation worldwide. Mortality rates
for patients hospitalised with CAP approach 30%, especially in those admitted to an intensive care unit
(ICU) [1–4]. Diagnostic testing in CAP has the potential to improve individual patient management,
reducing the risk of clinical failure and death, and to generate epidemiological data, informing the
selection of appropriate empirical antibiotic therapy. Unfortunately, these advantages are counterbalanced
by high healthcare costs associated with diagnostic testing and low sensitivity of these tests to identify
pathogens causing CAP [5, 6].
Considering both the benefits and limitations of diagnostic testing, several international scientific societies
have published guidelines on effective diagnostic testing strategies for hospitalised patients with CAP.
However, important differences exist between recommendations of different societies [7]. These
recommendations are mainly based on expert opinion given the scarcity of published evidence. In
particular, substantial differences can be found between the two most cited international guidelines on
CAP: the 2007 Infectious Diseases Society of America (IDSA)/American Thoracic Society (ATS) and the
2011 European Respiratory Society (ERS) guidelines [8, 9]. Limited data are available of real-life diagnostic
testing practices for hospitalised patients with CAP and whether real-life diagnostic testing practices are
concordant with the 2007 IDSA/ATS and 2011 ERS guideline recommendations [10–12].
This study aimed to describe real-life microbiological testing of adults hospitalised with CAP, evaluate the
influence of geography and disease severity on microbiological testing practices, and assess the
concordance of real-life microbiological testing with the two most cited international guidelines,
specifically the 2007 IDSA/ATS and the 2011 ERS guidelines.
Methods
Study design, setting and participants
We performed a secondary analysis of an international, multicentre, observational, prospective cohort
study using the Global Initiative for Methicillin-resistant Staphylococcus aureus Pneumonia (GLIMP)
database [13]. GLIMP was conducted among 222 hospitals in 54 countries over 4 days, with 1 day per
month randomly selected during March, April, May and June 2015. All adult patients (aged
>18 years) hospitalised for CAP at the participating centres during the four study days were screened
by GLIMP investigators and included in this secondary analysis. Patients hospitalised with a
diagnosis of hospital-acquired or ventilator-associated pneumonia were excluded. The GLIMP
coordinating centre was located at the University of Texas Health San Antonio (San Antonio, TX,
USA). The coordinating centre received expedited project approval by the institutional review board
(number HSC20150184E). The review board waived the need for receipt of informed consent due to
the nature of the study. Institutional review board approval was obtained by the site investigators at
each individual centre. A detailed description of the GLIMP organisation and methodologies has
been previously published [13].
Study outcomes
The primary outcome of this study was describing real-life microbiological testing among patients
hospitalised with CAP, including the frequency of testing, laboratory technique used and patients’
characteristics by testing status (tested patients versus not tested patients). This study had also two
secondary outcomes. The first was to evaluate the influence of geography and disease severity on testing
practices. ICU admission, invasive mechanical ventilation, vasopressors, and combined administration of
vasopressors and invasive mechanical ventilation were used as measures of disease severity. The second
was to evaluate the concordance of real-life microbiological testing with the 2007 IDSA/ATS and the 2011
ERS guidelines for CAP.
Study definitions
CAP was defined by evidence of new pulmonary infiltrates on thoracic imaging (chest radiograph,
computed tomography or ultrasound) during the first 48 h of hospitalisation and at least one of the
following criteria: new or increased cough with or without sputum production or with purulent respiratory
secretions; fever or hypothermia (documented rectal or oral temperature ⩾37.8°C or <36°C, respectively);
and evidence of systemic inflammation, such as abnormal white blood cell count (leukocytosis
(>10000 cells·mL−1), leukopenia (<4000 cells·mL−1) or bandaemia (>10%)) and increased C-reactive
protein or procalcitonin concentrations above the local upper limit of normal. Hospitalisation was defined
as admission at an inpatient service and subsequent stay for ⩾24 h. Methicillin-resistant Staphylococcus
aureus was defined according to the Clinical and Laboratory Standards Institute (CLSI) guidelines, in
which the minimum inhibitory concentration was ⩾4 µg·mL−1 to oxacillin. Production of
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extended-spectrum β-lactamase was defined according to the CLSI guidelines via broth microdilution or
disk diffusion clavulanate inhibition test.
Diagnostic testing was defined as concordant with the 2007 IDSA/ATS guidelines if recommended tests
were performed and non-recommended tests were not performed. Similarly, diagnostic testing was defined
as concordant with the 2011 ERS guidelines if recommended tests were performed and non-recommended
tests were not performed. The tests considered in this study as recommended or non-recommended by the
IDSA/ATS and ERS guidelines are presented in table 1. Over-testing was defined as a condition where
tests not required were performed. Under-testing was defined as a condition where required tests were not
performed.
Statistical analysis
Continuous variables were presented as medians with interquartile range. Categorical variables were
presented as frequencies and percentages of the specified group. Comparisons between groups were made
with the Fisher exact test or the Kruskal–Wallis test, as appropriate. A two-sided p-value of <0.05 was
considered statistically significant. Statistical analyses were performed using SPSS Statistics, version 24,
software (IBM, Armonk, NY, USA).
Results
Among 3702 patients, 3217 (86.9%) had at least one diagnostic test performed, with 1173 (36.5%) patients
with at least one pathogen detected by diagnostic testing. Variables significantly associated with the
performance of diagnostic testing are presented in table 2. When patients from whom at least one
pathogen was detected were compared with patients from whom no pathogens were detected, we found
the former group more commonly presented the following conditions: bronchiectasis, tracheostomy, at
least one respiratory comorbidity, hypertension, HIV infection, pervious infections, previous healthcare
exposure, severe CAP, ICU admission, mechanical ventilation and use of vasopressors (table 2).
TABLE 1 Tests considered as recommended or not recommended by the Infectious Diseases
Society of America (IDSA)/American Thoracic Society (ATS) and European Respiratory Society
(ERS) guidelines
IDSA/ATS recommendations ERS recommendations
Blood culture Recommended in case of ICU
admission, leukopenia, alcohol
abuse, chronic severe liver disease,
asplenia, positive pneumococcal
urinary antigen test and presence
of pleural effusion
Recommended in all
patients hospitalised
with CAP
Sputum culture Recommended in case of ICU
admission, alcohol abuse, severe
obstructive or structural lung
disease, positive Legionella urinary
antigen test, positive pneumococcal
urinary antigen test and presence
of pleural effusion
Recommended in case of
purulent sputum sample
Bronchoalveolar lavage culture Recommended in case of intubation Recommended in case of
intubation
Legionella urinary antigen test Recommended in case of ICU
admission, alcohol abuse and
presence of pleural effusion
Recommended in all
patients hospitalised
with severe CAP
Pneumococcal urinary antigen test Recommended in case of ICU
admission, leukopenia, alcohol
abuse, chronic severe liver disease,
asplenia and pleural effusion
Recommended in all
patients hospitalised
with severe CAP
Acute-phase serology for
Chlamydophila pneumoniae,
Mycoplasma pneumoniae, and
Legionella species
Not recommended Not recommended
ICU: intensive care unit; CAP: community-acquired pneumonia.
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TABLE 2 Baseline characteristics of adult inpatients with community-acquired pneumonia by testing status and by pathogen
detection
Testing status Pathogen detection
Not tested Tested p-value Not detected Detected p-value
Patients 485 3217 2044 1173
Demographic characteristics
Age 71.0 (54.0–81.0) 68.0 (54.0–80.0) 0.03 70.0 (55.0–81.0) 65.0 (50.0–77.0) <0.01
Male sex 255 (52.6) 1888 (58.7) 0.01 1173 (57.4) 715 (61.0) 0.04
Underweight 14 (5.2) 152 (7.4) 0.19 83 (6.5) 69 (8.8) 0.06
Obesity 64 (13.2) 513 (15.9) 0.12 314 (15.4) 199 (17.0) 0.23
Respiratory past medical history
Active lung cancer 17 (3.5) 92 (2.9) 0.43 62 (3.0) 30 (2.6) 0.44
Asthma 26 (5.4) 235 (7.3) 0.12 149 (7.3) 86 (7.3) 0.97
Bronchiectasis 9 (1.9) 169 (5.3) <0.01 76 (3.7) 93 (7.9) <0.01
Chronic aspiration 39 (8.0) 218 (6.8) 0.31 137 (6.7) 81 (6.9) 0.83
COPD 96 (19.8) 840 (26.1) 0.01 517 (25.3) 323 (27.5) 0.16
Current or former smoker 121 (24.9) 1124 (34.9) <0.01 709 (34.7) 415 (35.4) 0.69
Interstitial lung disease 4 (0.8) 91 (2.8) 0.01 65 (3.2) 26 (2.2) 0.11
Obstructive sleep apnoea 7 (1.4) 123 (3.8) 0.01 78 (3.8) 45 (3.8) 0.98
Home oxygen therapy 14 (2.9) 210 (6.5) <0.01 123 (6.0) 87 (7.4) 0.12
Lung transplant 0 (0.0) 7 (0.2) 0.30 2 (0.1) 5 (0.4) 0.06
Tracheostomy 3 (0.6) 50 (1.6) 0.11 14 (0.7) 36 (3.1) <0.01
At least one respiratory comorbidity 235 (48.5) 1917 (59.6) <0.01 1434 (56.7) 718 (61.2) 0.01
Cardiovascular past medical history
Arrhythmia 69 (14.2) 458 (14.2) 1.00 307 (15.0) 151 (12.9) 0.09
Coronary artery disease 69 (14.2) 528 (16.4) 0.22 325 (15.9) 203 (17.3) 0.30
Heart failure 64 (13.2) 421 (13.1) 0.95 270 (13.2) 151 (12.9) 0.79
Hypertension 201 (41.4) 1454 (45.2) 0.12 973 (47.6) 481 (41.0) <0.01
Stroke 55 (11.3) 251 (7.8) 0.01 168 (8.2) 83 (7.1) 0.25
Immunosuppressive conditions
Active solid tumour 40 (8.2) 247 (7.7) 0.66 164 (8.0) 83 (7.1) 0.33
AIDS 8 (1.6) 57 (1.8) 0.85 24 (1.2) 33 (2.8) <0.01
Aplastic anaemia 1 (0.2) 13 (0.4) 0.51 8 (0.4) 5 (0.4) 0.88
Asplenia 0 (0.0) 12 (0.4) 0.18 5 (0.2) 7 (0.6) 0.12
Chemotherapy in the last 3 months 9 (1.9) 136 (4.2) 0.01 83 (4.1) 53 (4.5) 0.54
Haematological malignancy 11 (2.3) 151 (4.7) 0.02 93 (4.5) 58 (4.9) 0.61
HIV infection 16 (3.3) 107 (3.3) 0.98 56 (2.7) 51 (4.3) 0.01
Neutropenia 4 (0.8) 44 (1.4) 0.32 29 (1.4) 15 (1.3) 0.74
Steroids use 24 (4.9) 270 (8.4) 0.01 174 (8.5) 96 (8.2) 0.75
At least one immunosuppressive condition 74 (15.3) 591 (18.4) 0.09 356 (17.4) 235 (20.0) 0.07
Other chronic medical conditions
Chronic renal failure 50 (10.3) 350 (10.9) 0.71 241 (11.8) 109 (9.3) 0.03
Cirrhosis 6 (1.2) 64 (2.0) 0.26 36 (1.8) 28 (2.4) 0.22
Diabetes mellitus 92 (19.0) 690 (21.4) 0.21 448 (21.9) 242 (20.6) 0.39
Haemodialysis 1 (0.2) 51 (1.6) 0.02 32 (1.6) 19 (1.6) 0.91
Liver disease 11 (2.3) 129 (4.0) 0.06 75 (3.7) 54 (4.6) 0.19
Mental illness 33 (6.8) 221 (6.9) 0.96 146 (7.1) 75 (6.4) 0.42
Dementia 74 (15.3) 334 (10.4) <0.01 228 (11.2) 106 (9.0) 0.06
Previous infections
Prior ESBL 0 (0.0) 55 (1.7) <0.01 27 (1.3) 28 (2.4) 0.03
Prior MRSA 5 (1.0) 81 (2.5) 0.04 34 (1.7) 47 (4.0) <0.01
Prior mycobacterial disease 7 (1.4) 89 (2.8) 0.09 42 (2.1) 47 (4.0) <0.01
Prior Pseudomonas 4 (0.8) 97 (3.0) <0.01 32 (1.6) 65 (5.5) <0.01
Previous healthcare exposure#
Lower respiratory tract infection 106 (21.9) 935 (29.1) <0.01 667 (26.4) 374 (31.9) <0.01
Emergency room admission 120 (24.7) 981 (30.5) 0.01 708 (28.0) 393 (33.5) <0.01
Hospitalisation 128 (26.4) 1035 (32.2) 0.01 771 (30.5) 392 (33.4) 0.07
Home antibiotic infusion therapy 21 (4.3) 141 (4.4) 0.96 94 (3.7) 68 (5.8) <0.01
Intravenous antibiotics 89 (18.4) 816 (25.4) <0.01 569 (22.5) 336 (28.6) <0.01
Oral antibiotics 166 (34.2) 1226 (38.1) 0.10 917 (36.3) 475 (40.5) 0.01
Continued
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Of the 3702 patients hospitalised with CAP and included in this study, diagnostic testing was as
follows: 2633 (71.1%) had blood cultures, 2287 (61.8%) had sputum cultures, 1113 (30.1%) had
Legionella urinary antigen testing, 1110 (30.0%) had pneumococcal urinary antigen testing, 553
(14.9%) had viral testing, 325 (8.8%) had acute-phase serology, 312 (8.4%) had bronchoalveolar lavage
(BAL) cultures and 117 (3.2%) had pleural fluid cultures. Blood, sputum, BAL cultures, pleural fluid
cultures and viral testing were more frequently obtained among patients undergoing invasive
mechanical ventilation compared to patients not receiving invasive mechanical ventilation. In contrast,
when ICU admission, vasopressor administration, or combined vasopressor and invasive mechanical
ventilation administration were used as measures of disease severity, only blood cultures, BAL cultures
and viral testing were significantly more common among patients with a severe disease (table 3). Of
the 8450 diagnostic tests performed, 12.9% yielded a positive result. Specifically, 38.8% of the BAL
cultures, 28.2% of the viral testing, 19.4% of acute-phase serology testing, 17.7% of sputum cultures,
11.7% of pneumococcal urinary antigen testing, 11.1% of pleural fluid cultures, 6.7% of blood cultures
and 2.2% of Legionella urinary antigen testing led to the detection of at least one pathogen, for a total
of 1362 pathogens detected. Bacteria, viruses and fungi accounted for 83.0%, 14.1% and 2.9% of the
pathogens detected, respectively. Streptococcus pneumoniae was the most frequently encountered
pathogen (n=268), followed by Staphylococcus aureus (n=188), influenza viruses (n=154) and
Pseudomonas aeruginosa (n=133).
When the performance of diagnostic testing was compared among patients admitted at participating
hospitals in North America, South America, Africa, Asia, Europe and Oceania, significant differences were
identified (table 4). Performance of at least one test ranged from 82.1% among patients hospitalised in
Africa to 97.8% among patients hospitalised in Asia. While blood cultures were obtained in approximately
70–90% of patients hospitalised in North America, South America, Europe, Asia and Oceania, only 41.7%
of patients in participating African hospitals had blood cultures (p<0.01). Similarly, viral testing was
performed in 10–20% of patients hospitalised in North America, South America, Europe, Asia and
TABLE 2 Continued
Testing status Pathogen detection
Not tested Tested p-value Not detected Detected p-value
Current pneumonia episode
ICU admission 33 (6.8) 601 (18.7) <0.01 275 (13.5) 326 (27.8) <0.01
Mechanical ventilation 28 (5.8) 634 (19.7) <0.01 312 (15.3) 322 (27.5) <0.01
Vasopressors 9 (1.9) 233 (7.2) <0.01 91 (4.5) 142 (12.1) <0.01
Data are presented as n, median (interquartile range) or n (%), unless otherwise stated. COPD: chronic obstructive pulmonary disease; ESBL:
extended-spectrum β-lactamase; MRSA: methicillin-resistant Staphylococcus aureus; ICU: intensive care unit. #: in the previous 12 months.
Bold indicates statistical significance at p<0.05.
TABLE 3 Microbiological tests performed among adult inpatients with community-acquired pneumonia by disease severity
Total ICU Invasive mechanical ventilation
and vasopressors
No Yes p-value No Yes p-value
Patients 3702 3068 634 3529 173
Blood culture 2633 (71.1) 2110 (68.8) 523 (82.5) <0.01 2477 (70.2) 156 (90.2) <0.01
Sputum culture 2287 (61.8) 1895 (61.8) 392 (61.8) 0.98 2182 (61.8) 105 (60.7) 0.76
Bronchoalveolar lavage culture 312 (8.4) 179 (5.8) 133 (21.0) <0.01 268 (7.6) 44 (25.4) <0.01
Pleural fluid culture 117 (3.2) 90 (2.9) 27 (4.3) 0.08 108 (3.1) 9 (5.2) 0.12
Pneumococcal urinary antigen 1110 (30.0) 939 (30.6) 171 (27.0) 0.07 1054 (29.9) 56 (32.4) 0.48
Legionella urinary antigen 1113 (30.1) 939 (30.6) 174 (27.4) 0.11 1051 (29.8) 62 (35.8) 0.09
Acute-phase serology 325 (8.8) 258 (8.4) 67 (10.6) 0.08 307 (8.7) 18 (10.4) 0.44
Viral testing 553 (14.9) 390 (12.7) 163 (25.7) <0.01 482 (13.7) 71 (41.0) <0.01
Data are presented as n or n (%), unless otherwise stated. ICU: intensive care unit. Bold indicates statistical significance at p<0.05.
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TABLE 4 Microbiological tests performed among adult inpatients with community-acquired
pneumonia by geographic area
Continent Rest of the world p-value
Blood culture
North America 434 (82.0) 2199 (69.3) <0.01
South America 202 (92.7) 2431 (69.8) <0.01
Africa 65 (41.7) 2568 (72.4) <0.01
Asia 294 (70.8) 2339 (71.2) 0.89
Europe 1609 (68.6) 1024 (75.4) <0.01
Oceania 29 (72.5) 2604 (71.1) 0.85
Sputum culture
North America 286 (54.1) 2001 (63.1) <0.01
South America 95 (43.6) 2192 (62.9) <0.01
Africa 92 (59.0) 2195 (61.9) 0.46
Asia 305 (73.5) 1982 (60.3) <0.01
Europe 1496 (63.8) 791 (58.2) <0.01
Oceania 13 (32.5) 2274 (62.1) <0.01
Bronchoalveolar lavage culture
North America 68 (12.9) 244 (7.7) <0.01
South America 15 (6.9) 297 (8.5) 0.40
Africa 10 (6.4) 302 (8.5) 0.35
Asia 48 (11.6) 264 (8.0) 0.02
Europe 171 (7.3) 141 (10.4) <0.01
Oceania 0 (0.0) 312 (8.5) 0.05
Pleural fluid culture
North America 13 (2.5) 104 (3.3) 0.32
South America 13 (6.0) 104 (3.3) 0.02
Africa 12 (7.7) 105 (3.0) <0.01
Asia 12 (2.9) 105 (3.2) 0.74
Europe 67 (2.9) 50 (3.7) 0.17
Oceania 0 (0.0) 117 (3.2) 0.25
Pneumococcal urinary antigen
North America 55 (10.4) 1055 (33.2) <0.01
South America 17 (7.8) 1093 (31.4) <0.01
Africa 2 (1.3) 1108 (31.2) <0.01
Asia 22 (5.3) 1088 (33.1) <0.01
Europe 1014 (43.3) 96 (7.1) <0.01
Oceania 0 (0.0) 1110 (30.3) <0.01
Legionella urinary antigen
North America 93 (17.6) 1020 (32.1) <0.01
South America 1 (0.5) 1112 (31.9) <0.01
Africa 1 (0.6) 1112 (31.4) <0.01
Asia 30 (7.2) 1083 (32.9) <0.01
Europe 988 (42.2) 125 (9.2) <0.01
Oceania 0 (0.0) 1113 (30.4) <0.01
Acute-phase serology
North America 22 (4.2) 303 (9.5) <0.01
South America 11 (5.0) 314 (9.0) 0.04
Africa 9 (5.8) 316 (8.9) 0.18
Asia 17 (4.1) 308 (9.4) <0.01
Europe 263 (11.2) 62 (4.6) <0.01
Oceania 3 (7.5) 322 (8.8) 0.77
Viral testing
North America 83 (15.7) 470 (14.8) 0.60
South America 25 (11.5) 528 (15.2) 0.14
Africa 2 (1.3) 551 (15.5) <0.01
Asia 78 (18.8) 475 (14.5) 0.02
Europe 361 (15.4) 192 (14.1) 0.30
Oceania 4 (10.0) 549 (15.0) 0.38
Continued
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Oceania, and in 1.3% of patients admitted to African hospitals (p<0.01). Pneumococcal and Legionella
urinary antigen tests were performed in >40% of the patients admitted in European hospitals and in <20%
of the patients hospitalised in the remaining continents (p<0.01). Acute-phase serology for Chlamydophila
pneumoniae, Mycoplasma pneumoniae and Legionella species was more common in Europe (11.2%) than
elsewhere (4.6%) (p<0.01).
TABLE 4 Continued
Continent Rest of the world p-value
At least one test done
North America 489 (92.4) 2728 (86.0) <0.01
South America 204 (93.6) 3013 (86.5) <0.01
Africa 128 (82.1) 3089 (87.1) 0.07
Asia 406 (97.8) 2811 (85.5) <0.01
Europe 1955 (83.4) 1262 (92.9) <0.01
Oceania 35 (87.5) 3182 (86.9) 0.91
Data are presented as n (%), unless otherwise stated. Bold indicates statistical significance at p<0.05.
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FIGURE 1 Discordance of diagnostic testing with the a) 2007 Infectious Diseases Society of America/American Thoracic Society (ATS) guidelines
and b) 2011 European Respiratory Society (ERS) guidelines for community-acquired pneumonia by geographic area. Over: over-testing; under:
under-testing; over/under: over-testing and under-testing.
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Diagnostic testing was concordant with the IDSA/ATS and ERS recommendations in 16.7% and 23.9% of
the patients, respectively. When the overall study population was analysed, over-testing and under-testing
were reported in 59.3% and 19.1% of the IDSA/ATS-discordant patients, respectively (figure 1). Among
IDSA/ATS-discordant patients, blood cultures performed without indications accounted for the majority
of over-testing, while the lack of pneumococcal urinary antigen test was responsible for a significant
percentage of under-testing. Over-testing and under-testing were documented in 29.3% and in 42.0% of
the ERS-discordant patients, respectively (figure 1). Among ERS-discordant patients, pneumococcal and
Legionella urinary antigen tests performed without an indication accounted for the majority of
over-testing, while under-testing was mainly due to the lack of obtaining blood cultures when indicated.
IDSA/ATS concordance was more common in Europe than in North America (21.5% versus 9.8%;
p<0.01), while ERS concordance was more common in North America than in Europe (33.5% versus
19.5%; p<0.01).
Discussion
This international, multicentre, point-prevalence study provides a high-quality, real-life picture of
diagnostic testing in patients hospitalised with CAP. At least one microbiological test was performed in the
vast majority of patients hospitalised with CAP and led to an aetiological diagnosis in one-third of patients
tested. Geographic area and disease severity influenced testing frequency. Our study also highlights a
significant discordance of real-life diagnostic testing compared to recommended testing in the 2007 IDSA/
ATS and 2011 ERS guidelines for CAP management in adults. Several crucial points could be raised by
our findings.
First, a pathogen was identified in one-third of adult inpatients with CAP. This pathogen-detection yield is
similar to previously reported investigations [14–21] and consistent with the EPIC (Etiology of Pneumonia
in the Community) study [1]. Despite extensive laboratory testing, the EPIC study identified a pathogen in
38% of 2259 patients hospitalised with CAP in the USA. The low pathogen-detection yield reported in this
and other CAP studies highlights how limited our understanding is of CAP aetiologies among adult
inpatients and how current empirical antimicrobial recommendations are based on weak evidence. Studies
aimed at collecting as much data as possible to identify the aetiology using state-of-the-art diagnostic
techniques and innovative pathogen-discovery approaches are urgently needed. Furthermore, aetiological
studies should use novel analytical techniques in order to incorporate evidence from multiple specimens to
account for the imperfect sensitivity and specificity of the diagnostic tests used [22]. Once a more accurate
estimate of the aetiological distribution of CAP among adult inpatients is available, empirical antimicrobial
recommendations should be updated.
Secondly, our study showed the existence of a strong association between pneumonia severity and
performance of diagnostic testing, in accordance with IDSA/ATS and ERS recommendations. As a
consequence, pneumonia severity was also associated with an increased probability of pathogen detection.
Exploring the true determinants of pathogen detection would have required a systematic and universal
testing strategy and, for this reason, it was out of the scope of this study.
Thirdly, our study confirmed the differing diagnostic yield of various diagnostic tests. Specifically, only
6.7% of blood cultures yielded a positive result, confirming the low sensitivity of blood cultures for
revealing the aetiology of CAP, similar to the findings of other studies [16–23]. In contrast, BAL cultures
were characterised by a high diagnostic yield (38.8%). While impractical and potentially associated with
complications, BAL cultures represent an effective diagnostic tool for patients with severe infections, who
may benefit the most from a targeted antimicrobial regimen. Indeed, a randomised trial by VAN DER EERDEN
et al. [24] showed a statistically significant difference in mortality among ICU patients receiving empirical
broad-spectrum antimicrobials (91%) versus patients receiving pathogen-directed antimicrobials (45%).
Fourthly, our analysis described a significant geographic variation in diagnostic testing strategies. We could
speculate that the economical restraints of African health systems accounted for the reduced number of
blood cultures and viral tests performed in this setting. Laboratory infrastructure to support diagnostic
microbiological testing is limited in most African countries: bacteriological culture or molecular techniques
that form the mainstay of CAP diagnostics in well-resourced settings are often lacking in Africa [25, 26].
In contrast, the seasonality and the epidemiological relevance of respiratory viruses, such as avian-origin
influenza A and Middle East respiratory syndrome coronavirus, may have favoured the performance of
viral testing in Asia [27, 28].
Fifthly, our study is among the first to evaluate the concordance of real-life diagnostic testing with
international guidelines. To the best of our knowledge, only JENKINS et al. [12] made a similar attempt.
They analysed the concordance of diagnostic testing practices retrospectively in a cohort of adult inpatients
with CAP with the 2007 IDSA/ATS guidelines and reported over-testing with blood cultures. Our study
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revealed that real-life diagnostic testing was not concordant with IDSA/ATS or ERS guidelines in the vast
majority of the patients. Specifically, the discordance with the IDSA/ATS guidelines was mainly due to
over-testing. This situation may be explained by the restrictive testing recommended by the IDSA/ATS
guidelines. Of note, under-testing was also a cause of discordance with the IDSA/ATS guidelines and was
more frequently encountered in North America than in Europe. Discordance with ERS guidelines was
mainly due to under-testing, as a result of the extensive testing approach recommended by these
guidelines. Over-testing was also identified as a cause of discordance with the ERS guidelines. This event
was more frequently reported in Europe than in North America. We were intrigued by European
clinicians’ extensive ordering of diagnostic tests, even beyond what is recommended by the ERS guidelines.
Insurance and healthcare system-related factors may have shaped the diagnostic approach both of
European and North American clinicians. Nonetheless, the significant discrepancies between real-life
diagnostic testing and IDSA/ATS/ERS recommended testing is worrisome and further studies aimed at
assessing the clinical and economic implications of the testing approach proposed by the IDSA/ATS
guidelines, the testing approach proposed by the ERS guidelines, and real-life diagnostic testing are
needed.
Finally, this study has important strengths and limitations. To our knowledge, GLIMP is the first study to
enrol a large and diverse group of adult patients hospitalised with CAP across six continents, providing a
detailed, real-world picture of CAP diagnostic testing around the world. Our ability to assess the
concordance of real-life diagnostic testing with IDSA/ATS and ERS guideline recommendations was
affected by the lack of information about recent travel, failure of outpatient antibiotic therapy, presence of
cavitary infiltrates, lymphopenia, and feasibility of sputum collection in the GLIMP database. Similarly,
incomplete data regarding presence of pleural effusions and clinical and epidemiological determinants of
Legionella infection limited the accuracy our findings, probably leading to an inflation of our over-testing
estimates. Finally, due to its cross-sectional design, our study did not provide CAP outcome data.
In conclusion, our understanding of the aetiologies of CAP among hospitalised adults is scarce, limiting
the accuracy of empirical antimicrobial regimens. Disease severity and geography are associated with
differences in testing approaches. The wide discordance between IDSA/ATS/ERS recommendations and
real-life testing strategies should prompt future studies to evaluate the clinical and economic implications
of different testing approaches and investigate the reasons for these differences.
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